{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-020519","form_type":"8-K","ticker":"SRZN","cik":"0001824893","company_name":"Surrozen, Inc./DE","filed_at":"2023-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.910791+00:00","generated_at":"2026-06-15T06:58:21.364114+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Surrozen Q1 net loss widens to $14.3M; cash at $61.7M; SZN-043 and SZN-1326 trials enroll","bullets":["Net loss of $14.3M vs $7.9M in Q1 2022, driven by $1.2M restructuring charges and higher G&A.","Cash, equivalents and marketable securities $61.7M, down from $75.8M at Dec 31, 2022.","R&D expenses $8.1M, down from $9.4M YoY due to January 2023 restructuring reducing workforce ~25%.","SZN-043 Phase 1a enrollment ongoing in chronic liver disease; safety data expected end of 2023.","SZN-1326 Phase 1a re-initiated in Q2 2023; safety data also expected by end of 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-020519","json":"https://secwatch.observer/filing/0000950170-23-020519.json","markdown":"https://secwatch.observer/filing/0000950170-23-020519.md","text":"https://secwatch.observer/filing/0000950170-23-020519.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1824893/000095017023020519/0000950170-23-020519-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1824893/000095017023020519/srzn-20230510.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T06:58:21.364114+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f95a4cd0005468257403bfa65756904bd09fed8e","claim":"Surrozen, Inc./DE reported first quarter ended March 31, 2023 results: net income $14.3 million.","evidence_excerpt":"Surrozen, Inc. (the \"Company\") issued a press release announcing its financial results for the quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1824893/000095017023020519/0000950170-23-020519-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Net income","value":"$14.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}